# Polymorphism of  IL-1B  rs16944 (T/C) associated with serum levels  of IL-1β affects seizure susceptibility in ischemic stroke patients  

\*Xiaojun Ma , \*Liangwei Sun , Xiaoli Li , Yanlu Xu , Qingyan Zhang  

1 	Department of Geriatrics, Shandong Provincial Third Hospital, Jinan, China 2 	Department of Neurology, Shandong Provincial Third Hospital, Jinan, China 3 	Institute of Scientific Devices, Beihang University, Beijing, China  

A – research concept and design; B – collection and/or assembly of data; C – data analysis and interpretation;
 D – writing the article; E – critical revision of the article; F – final approval of the article  

Adv Clin Exp Med . 2023;32(1):23–29  

Advances in Clinical and Experimental Medicine, ISSN 1899–5276 (print), ISSN 2451–2680 (online)  

Address for correspondence Xiaoli Li E-mail: li xiao li 20080101@126.com  

# Abstract  

Background.  Seizures and the subsequent development of epilepsy after stroke may not only hinder pa­ tient’s recovery but also increase the risk of complications. Interleukin (IL)-  $.1\upbeta$   has been shown to be acutely  up regulated after ischemic stroke and play a role in the recurrence of seizures following the first epileptic  seizure in patients suffering an ischemic stroke. Meanwhile, variants of the  IL-1B  gene encoding IL-  $1\upbeta$   are  involved in the stimulation of febrile seizures.  

Funding sources None declared  

Conflict of interest None declared  

Objectives.  To study the potential associations of the 5 polymorphisms of the  IL-1B  gene with seizure  susceptibility in ischemic stroke patients, and to explore the possible mechanisms.  

\*Xiaojun Ma and Liangwei Sun contributed equally  to this work  

Materials and methods.  A total of 856 ischemic stroke patients were allocated into the control group  (patients without post-stroke seizures) and the case group (patients with post-stroke seizures). The  IL-1B   polymorphisms rs10490571 (T/C), rs114363 (C/T), rs1143623 (G/C), rs16944 (T/C), and rs2853550 (A/G) were  detected using TaqMan SNP genotyping assays, and serum IL $\cdot\upbeta$   levels were measured using the enzymelinked immuno s or bent assay (ELISA). Demographic data, clinical characteristics and cerebro vascular disease  risk factors at admission were collected. Multivariate analysis was performed to determine independent  associations, and IL $.1\upbeta$   levels were compared using analysis of variance (ANOVA) followed by a post hoc test.  

Received on April 9, 2022 Reviewed on July 24, 2022 Accepted on August 11, 2022  

Published online on September 12, 2022  

Results.  In 74 patients   $(8.6\%,$   74/856), post-stroke seizures occurred within 1 year of stroke onset. The mul­ tivariate analysis showed that the rs16944 polymorphism of  IL-1B , cortical involvement and National Institutes  of Health Stroke Scale (NIHSS) score on admission were correlated with post-stroke seizures after adjusting  for stroke laterality, thr ombo lysis, use of statins, and IL-1B rs10490571. The IL-1B rs16944 TT (odds ratio (OR):   $1.923,95\%$   confidence interval   $(95\%\,(])$  ): 1.257–4.185) and TC genotypes (OR: 1.469,  $95\%$  CI: 1.130–2.974)  were associated with a significantly increased risk of post-stroke seizures compared to the CC genotype.  One-way ANOVA for IL $\upbeta$   levels demonstrated a tendency for higher levels in   $\daleth>\daleth(\zeta>\zeta(\zeta$   genotypes  (6.41 compared to 4.53 compared to 2.10 pg/mL, respectively).  

Conclusions.  The  IL-1B  rs16944 polymorphism had an independent association with seizure susceptibility  after ischemic stroke. The mechanism might be associated with the regulation of IL $\cdot\upbeta$   levels.  

Key words:  polymorphism, multivariate analysis,  IL-1B  rs16944   $\left(\lceil/\zeta\right)$  , post-stroke seizures, IL $1\upbeta$   levels  

DOI 10.17219/acem/152738  

# Background  

Strokes are the   $2^{\mathrm{nd}}$   leading cause of preventable deaths  around the world and the primary cause of long-term dis­ ability.  In China, the stroke burden has been increasing  over the past 30 years. The age-standardized incidence has  risen to 246.8/100,000 person-years, and the age-standard­ ized mortality to 114.8/100,000 person-years.  Ischemic  stroke, which accounts for  $75{-}80\%$   of all strokes, is the most  common cause of seizures among the elderly and is the pre­ dominant cause of seizures among the adults.  Seizures  and the subsequent development of epilepsy after stroke  may not only hinder patient’s recovery but also increase  the risk of complications.  With demographic changes,  the healthcare system is facing a challenge of an increas­ ing number of elderly people with post-stroke seizures.  Therefore, the identification and appropriate management  of stroke patients with an increased susceptibility for sei­ zures are crucial in stroke care. Interleukin (IL)-  $\cdot1\upbeta$   has been  demonstrated to be acutely up regulated after an ischemic  stroke and be involved in the recurrence of seizures fol­ lowing the first epileptic seizure in patients with ischemic  strokes.  At the same time, variants of the  $I L–I B$   gene  encoding IL $\cdot1\upbeta$   have been shown to be involved in the stim­ ulation of febrile seizures.  Additionally, the  IL-1B  poly­ morphisms rs16944, rs1143623, rs10490571, and rs2853550  were associated with the expression of   $\mathrm{{IL-18}}$  . However,  the correlations between these polymorphisms and poststroke seizures have not been analyzed.  

# Objectives  

In this study, the association of   $I L–I B$   polymorphisms  rs10490571, rs114363, rs16944, rs1143623, and rs2853550  with post-stroke seizures was determined using multi­ variate analysis. This study aimed to evaluate the poten­ tial associations of 5 polymorphisms of the   $I L–I B$   gene  with seizure susceptibility in ischemic stroke patients, and  to explore the possible mechanisms.  

# Materials and methods  

# Participants  

This case-control study was performed at the Shandong  Provincial Third Hospital (Jinan, China) between Sep­ tember 2018 and August 2019, and included 856 ischemic  stroke patients into the final analysis. Participants meet­ ing the following criteria were included: 1) acute first-ever  ischemic stroke definitively diagnosed using magnetic  resonance imaging (MRI) or computed tomography (CT);  2)  ${\geq}18$   years of age at the time of admission; 3) no previ­ ous history of seizures; 4) no potentially e pile p to geni c co­ morbid i ties such as cerebral venous thrombosis, cerebral  arte rio venous malformations, intra cranial tumors, etc.;  5) complete medical data; and 6) the ability to provide  written informed consent. Participants with the follow­ ing characteristics were excluded: 1) history of antiepi­ leptic drug therapy to prevent seizures or other diseases;  2) primary hemorrhagic stroke or transient ischemic at­ tacks; and 3) lost to follow-up or death before the follow-up.  This study received the approval from the Ethical Com­ mittee of Shandong Provincial Third Hospital (approval  No. SDTH-201813022).  

# Grouping  

All 856 ischemic stroke patients were allocated either  into the control group (patients without post-stroke sei­ zures) or the case group (patients with post-stroke sei­ zures), depending on the occurrence of a post-stroke  seizure within 1 year of the onset of ischemic stroke.  The diagnosis of seizure occurrence was determined us­ ing the definition provided by the International League  Against Epilepsy (ILAE).  

# Data collection  

We retrospectively collected the demographic data,  clinical characteristics and cerebro vascular disease risk  factors of participants at admission. The demographic  data included sex, age and body mass index (BMI), while  cerebro vascular disease risk factors included hypertension,  smoking, drinking, diabetes mellitus, coronary heart dis­ ease, dys lipid emi a, and atrial fibrillation. The clinical char­ act eris tics including stroke laterality, cortical involvement,  the National Institutes of Health Stroke Scale (NIHSS)  score at admission, Trial of ORG 10172 in Acute Stroke  Treatment (TOAST) classification (large artery atheroscle­ rosis, car dio embolism, small vessel occlusion, other deter­ mined, and undetermined), stroke treatment methods, and  duration from stroke onset to admission were collected.  

# Genotyping and measurement 
 of IL $\cdot18$   levels  

Peripheral blood samples were collected from all par­ ticipants and DNA was extracted from the blood samples  using the phenol-chloroform method. The concentra­ tion of DNA was measured using the optical density, and  the quality of DNA was assessed according to the 260/280  ratio. TaqMan ™  Pre-Designed SNP genotyping assays  (Applied Biosystems, Waltham, USA) were used to detect  the polymorphisms (C___29921173_20 for rs10490571,  C___9546529_30 for rs114363, C___1839943_10  for rs16944, C___1839941_10 for rs1143623, and  C___188872117_10 for rs2853550). Haploview software  v. 4.2 (Broad Institute, Cambridge, USA) was used to an­ alyze the Hardy–Weinberg equilibrium (HWE), as well  as allele and genotype frequencies.  

After the blood samples were centrifuged for   $10~\mathrm{min}$  at  $3000\,\mathbf{g}.$  , serum IL $\cdot1\upbeta$   levels were measured using the Hu­ man Interleukin $\cdot1\upbeta$   ELISA Kit (Baiaolaibo, Beijing, China).  

# Statistical analyses  

The IBM SPSS v. 22.0 (IBM Corp., Armonk, USA) was  used to perform all statistical analyses, and significance  was set at a two-sided p-value   $_{<0.05}$  . The Shapiro–Wilk  test was used to evaluate the normality of continuous  data. The Student’s t-test was used to compare the means  of normally distributed data between the case group and  the control group. The Mann–Whitney U test was used  to compare the pseudo-medians of non-normally distrib­ uted data. The  $\upchi^{2}$   test was used to compare the differences  in qualitative data between the case and control groups,  and the Fisher’s exact test was used when 1 or more cells  had an expected count of less than 5. To avoid the omission  of variables that might be meaningful and to determine  independent associations, the multivariate analysis was  performed for variables with a two-sided p-value   $\mathord{<\!0.10}$    in the univariate analysis, using a backward stepwise logis­ tic regression model. The IL $1\upbeta$   levels were compared using  analysis of variance (ANOVA) followed by post hoc testing  in ischemic stroke patients with different genotypes.  

# Results  

# General results  

A total of 74 participants   $(8.6\%,74/856)$   had post-stroke  seizures within 1 year of stroke onset. In the continuous  data, NIHSS score at admission was non-normally dis­ tributed and was expressed using the median and the  $1^{\mathrm{st}}$    and  $3^{\mathrm{rd}}$   quartile (Q1, Q3). The NIHSS score at admission  was 14 (12, 18) in the case group and 12 (10, 16) in the con­ trol group, and its pseudo-median was compared using  the Mann–Whitney U test. Other continuous data were  normally distributed, and their means were compared us­ ing Student’s t-tests. According to the results of univariate  analysis, stroke laterality, cortical involvement, thromboly­ sis, use of statins (Table 1), and NIHSS score on admission   $(Z=2.013\$  ,  $\mathsf{p}=0.044)$   were significantly different between  the control and case groups. Other variables were not sig­ nificantly different.  

# Genotyping results  

In 841 participants, these 5 single nucleotide polymor­ phisms (SNPs) were successfully genotyped. Sequencing  was further carried out for the SNPs that were not geno­ typed successfully. Finally, all 856 participants were suc­ cessfully genotyped for these 5 SNPs. As shown in Table 2,  the genotype frequencies of these 5 SNPs were not sig­ nificantly different from those predicted using the HWE.  

The  $\upchi^{2}$   test showed that the genotype frequencies of  IL-1B   rs16944 (degrees of freedom   $(\mathsf{d f})=2$  ,  $\chi^{2}=8.683$  ,  $\mathsf{p}=0.013,$    and rs10490571   $(\mathrm{df}=2$  , Fisher’s exact test,  $\mathsf{p}=0.030)$   were  significantly different between the case and control groups,  but rs1143623   $(\mathrm{d}\mathrm{f}=2,\upchi^{2}\,{=}\,0.261$  ,  $\mathsf{p}\,{=}\,0.878)$  , rs114363   $(\mathrm{df}=2$  ,  Fisher’s exact test,  $\mathsf{p}=0.456)$   and rs2853550 (  $(\mathrm{df}=2$  , Fisher’s  exact test,  $\mathsf{p}=0.698)$  ) were not.  

# Multivariate analysis  

The multivariate analysis was conducted for the follow­ ing variables: cortical involvement, stroke laterality, NI­ HSS score on admission, thr ombo lysis, use of statins,  $I L–I B$    rs16944, and  IL-1B  rs10490571. As demonstrated in Table 3,  the  $I L–I B$   polymorphism rs16944, cortical involvement and  NIHSS score on admission were correlated with post-stroke  seizures after adjusting for stroke laterality, thr ombo lysis,  use of statins, and  IL-1B  rs10490571. The  IL-1B  rs16944  TT and TC genotypes were associated with a significantly  increased risk of post-stroke seizures compared to the CC  genotype. Moreover, the odds ratio (OR) of the TT genotype  was higher than that of the TC genotype.  

# IL-1β levels  

The  $\mathrm{{IL-18}}$   levels in the case group were higher than that  of the control group (Student’s t-test,   ${\mathrm{df}}=854$  ,  $\mathsf{t}=2.683$  ,   $\mathsf{p}\,=\,0.008$  , Fig. 1A). One-way ANOVA for   $\mathrm{{IL-18}}$   levels  demonstrated a tendency for higher levels in TT com­ pared to TC and CC genotypes (Fig. 1B, 6.41 compared  to 4.53 compared to   $2.10\ \mathrm{{pg/mL}}$  , respectively; overall  test:   $\mathtt{F}=10.537,\,\mathtt{p}=0.007,$   post hoc results are presented  in Table 4).  

# Discussion  

The incidence of post-stroke seizures ranged from   $2\%$    to   $20\%$   with great variation.  Post-stroke seizures can  lead to additional complications, increased mortality and  longer initial hospitalizations, which substantially impact  the prognosis and quality of life in stroke patients.  

Inflammation is  extensively involved in  the  patho­ physiology of an ischemic stroke.  The expression of pro- inflammatory cytokines, including   $\mathrm{{IL-18}}$   and IL-6, have  been found to be significantly up regulated after an acute  stroke.  Neuro inflammation can result in hyper ex c it a bil­ ity, a ground base for seizures.  In the central nervous  system,   $I L–I B$   is a constitutive ly expressed gene that can  modulate both the expression and activity of ion channels  and exert a neuro troph ic factor-like activity.  The lev­ els of inflammatory cytokines in the   $\mathrm{{IL-18}}$   pathway can  act as biomarkers for neurologic diseases. The   $\mathrm{LL-1}\upbeta$   can  increase neuronal excitability through the  activation  of its endogenous receptor.  Following an initial insult  to the central nervous system, ongoing inflammation can  

Table 1.  Univariate analysis results of the differences regarding demographic data, risk factors for cerebro vascular diseases and clinical characteristics  between the case group and control group 
![](images/fc3bbd6bd7f9669380219f1d4a68b6ecb159b1c244b740e094bb05f6b666a3b5.jpg)  
 $M\pm\mathsf{S D}$   – mean  $\pm$   standard deviation; df – degrees of freedom; BMI – body mass index; TOAST – Trial of ORG 101072 in Acute Stroke Treatment; \* Fisher’s  exact test.  

change neuronal plasticity through several transcription­ ally mediated effects, which have the potential for aber­ rant and e pile p to geni c circuits.  Vezzani et al. reported  that   $\mathrm{{IL-18}}$   had pro convulsive effects on limbic seizures  in mice induced by electrical stimulation, bicuculine and  kainic acid.  Šutulović et al. showed that chronic pelvic  pain syndrome/chronic prostatitis (CPPS/CP) induced  with experimental λ-carrageenan can lead to an increased  susceptibility of rats to lindane-induced seizures through  the up regulation of IL-6 and IL $1\upbeta$   levels in the thalamus  and cerebral cortex.  

The mechanisms associated with the pro convulsive  effects of   $\mathrm{{IL-18}}$   remain unexplained. Several potential  mechanisms refer to   $\mathrm{{IL-18}}$   reducing the seizure thresh­ old through the induction of an intracellular   $\mathrm{Ca}2^{+}$   ion  surge and resultant modifications on voltage-dependent  ion channels 29 ;   $\mathrm{{IL-18}}$   stimulating the production of NO  in the brain 30 ;   $\mathrm{{IL-18}}$   inducing neuronal hyper ex c it a bil­ ity through the activation of the N-methyl-D-aspartate  receptor (NMDA-R) and stimulating the chronic release  of excitatory neurotransmitters 31 ; and IL $\boldsymbol{\cdot}1\upbeta$   inhibiting  $\mathrm{K^{+}}$    efflux, the recycling of gamma-aminobutyric acid (GABA)  receptors, and the uptake of excitatory neuro transmit­ ters by the glial population.  According to our results,  the levels of   $\mathrm{{IL-18}}$   in ischemic stroke patients with post- stroke seizures were significantly higher than in those  without post-stroke seizures.  

The expression of cytokines can be regulated by poly­ morphisms within the promoter regions of their genes.  Therefore, these promoter polymorphisms can influ­ ence the disease susceptibility by mediating the extent  of the secretory response of these cytokines.  The IL-1  

Table 2.  Results of Hardy–Weinberg equilibrium (HWE) testing in the case and control group 
![](images/7e5f98d20b52c1845512d5088498ab2688581a58766f486d1d7b538136441432.jpg)  
df – degrees of freedom; \*   Fisher’s exact test.  

Table 3.  Results of the multivariate analysis of the differences between the case and control group 
![](images/cc541e03c323ab065e20747a86486f395774b3ef0c6080ccb7d88747be14c6e8.jpg)  
OR – odds ratio;   $95\%$   CI –   $95\%$   confidence interval; NIHSS – National Institutes of Health Stroke Scale.  

Table 4.  Post hoc results of the analysis of the interleukin (IL)  $\cdot1\upbeta$   levels [pg/mL] 
![](images/7817c8bf8d960518db943157167efbcbc5d4a28f8791aac0a90306ba24534a84.jpg)  
 $95\%\subset|-95\%$   confidence interval.  

![](images/f5d15ea3bad0ab9ffc2041bdb2a91dae721c6f59bc07ac6caca45d54043ad1fc.jpg)  

Fig. 1.  Interleukin (IL)  $\cdot1\upbeta$   levels in the case  group and control group (A), and in different  genotypes (B)  $\mathsf{p}=0.008$   for the control group compared  to the case group;  $\mathsf{p}=0.011$   for TT compared  to TC;  $\mathsf{p}=0.002$   for TT compared to CC;   $\mathsf{p}=0.005$    for TC compared to  $\mathsf{C C}$  .Fig. 1. Interleukin (IL)-1β levels in the case group and control group (A), and in different genotypes (B)  

# Conclusions  

gene cluster contains  IL-1B ,  IL-1A  and  $I L$  -1RN  which are  located on chromosome 2q. The  $I L–I B$  , encoding   $\mathrm{{IL-18}}$  ,  is demonstrated to be 7020 base pairs in length and con­ tains numerous polymorphisms. Several SNPs within  the promoter region of  IL-1B  have been researched in vari­ ous infectious and inflammatory diseases.  Among them,  the  IL-1B  polymorphism rs16944 has been correlated with  IL-1β levels among rheumatoid arthritis patients in north  India and hence affects disease susceptibility in which  the T allele is directly associated with a higher IL $\boldsymbol{\cdot}1\upbeta$   ex­ pression.  The CT genotype of  IL1B  rs16944 has also  been shown to be associated with febrile seizure through  the up regulation of postictal   $\mathrm{{IL-1}}\upbeta$   levels in Korean chil­ dren.  The AA genotype of  IL-1B  rs2853550 has been  demonstrated to be correlated with a higher level of plasma   $\mathrm{{IL-18}}$   and, thus, an increased risk of ankylosing spon­ dylitis.  In addition, the polymorphisms of rs10490571  (T/C) and rs1143623 (G/C) can also affect   $\mathrm{{IL-18}}$   levels  in which the TC genotype of rs10490571 and the G allele  of rs1143623 are associated with a higher level of IL  $\cdot1\upbeta$  .   Therefore, multiple SNPs were included in our study.  

The  $I L–I B$   polymorphism rs16944 had an independent  association with seizure susceptibility in ischemic stroke  patients. The mechanism for this might be associated with  the regulation of IL $1\upbeta$   levels.  

# ORCID iDs  

Xiaojun Ma  $\circledast$   https://orcid.org/0000-0003-4158-4877 Liangwei Sun   $\circledast$   https://orcid.org/0000-0003-4158-4877 Xiaoli Li   $_\odot$   https://orcid.org/0000-0003-1484-176X Yanlu Xu  $\circledast$   https://orcid.org/0000-0002-0710-5484 Qingyan Zhang  $\circledast$   https://orcid.org/0000-0003-0869-5903  

# References  

1.	 Katan M, Luft A. Global burden of stroke.  Semin Neurol . 2018;38(2):
 208–211. doi:10.1055/s-0038-1649503 2.	 Wang W, Jiang B, Sun H, et al. Prevalence, incidence, and mortality  of stroke in China: Results from a nationwide population-based sur­ vey of 480 687 adults. Circulation. 2017;135(8):759–771. doi:10.1161/CIRCULATION AHA.116.025250 3.	 Galovic M, Ferreira-Atuesta C, Abraira L, et al. Seizures and epilepsy  after stroke: Epidemiology, biomarkers and management.  Drugs Aging . 
 2021;38(4):285–299. doi:10.1007/s40266-021-00837-7 4.	 Zöllner JP, Schmitt FC, Rosenow F, et al. Seizures and epilepsy in patients  with ischaemic stroke.  Neurol Res Pract . 2021;3(1):63. doi:10.1186
 /s42466-021-00161-w 5.	 Balami JS, Chen RL, Grunwald IQ, Buchan AM. Neurological compli­ cations of acute ischaemic stroke.  Lancet Neurol . 2011;10(4):357–371.  doi:10.1016/S1474-4422(10)70313-6 6.	 Kwan J. Stroke: Predicting the risk of poststroke epilepsy: Why and how?  Nat Rev Neurol . 2010;6(10):532–533. doi:10.1038/nrneurol.2010.140 7.	 Shen L, Yang J, Tang Y. Predictive values of the SeLECT score and IL-1β  for post-stroke epilepsy.  Neuro psych i a tr Dis Treat . 2021;17:2465–2472.  doi:10.2147/NDT.S324271 8.	 Clausen BH, Wirenfeldt M, Høgedal SS, et al. Characterization of  the TNF and IL-1 systems in human brain and blood after ischemic  stroke.  Acta Neuro path ol Commun . 2020;8(1):81. doi:10.1186/s40478- 020-00957-y 9.	 Zhang Q, Li G, Zhao D, Yang P, Shabier T, Tuerxun T. Association  between IL $\cdot1\upbeta$   and recurrence after the first epileptic seizure in isch­ emic stroke patients.  Sci Rep . 2020;10(1):13505. doi:10.1038/s41598- 020-70560-7 10.	 Choi J, Choi SA, Kim SY, et al. Association analysis of interleukin-  $\cdot1\upbeta,$    interleukin-6, and HMGB1 variants with postictal serum cytokine  levels in children with febrile seizure and generalized epilepsy with  febrile seizure plus.  J Clin Neurol . 2019;15(4):555–563. doi:10.3988/ jcn.2019.15.4.555  

According to the multivariate analysis, the  $I L–I B$   poly­ morphism rs16944 had an independent association with  seizure susceptibility in ischemic stroke patients after ad­ justing for con founders. The TT and TC genotypes sig­ nificantly increased the risk of post-stroke seizures com­ pared to CC. We further compared   $\mathrm{{IL-18}}$   levels among  different genotypes. The results showed that higher IL $1\upbeta$    levels were noted in TT compared to the TC genotype  compared to the CC genotype. Therefore, the mechanism  of the polymorphism of  IL-1B  rs16944 in affecting seizure  susceptibility in ischemic stroke patients might be associ­ ated with the regulation of IL $\cdot1\upbeta$   levels.  

# Limitations  

There were 2 main limitations to this study. The first  was the small sample size, especially for the case group.  Second, the study did not include all the SNPs associated  with the expression of IL-1β.  

11.	 Doria JW, Forgacs PB. Incidence, implications, and management of  seizures following ischemic and hemorrhagic stroke.  Curr Neurol  Neurosci Rep . 2019;19(7):37. doi:10.1007/s11910-019-0957-4

 12.	 Altman K, Shavit-Stein E, Maggio N. Post stroke seizures and epi­ lepsy: From proteases to maladaptive plasticity.  Front Cell Neurosci .  2019;13:397. doi:10.3389/fncel.2019.00397

 13.	 Wang JZ, Vyas MV, Saposnik G, Burneo JG. Incidence and manage­ ment of seizures after ischemic stroke: Systematic review and metaanalysis.  Neurology . 2017;89(12):1220–1228. doi:10.1212/WNL.00000
 00000004407

 14.	 Chohan S, Venkatesh P, How C. Long-term complications of stroke  and secondary prevention: An overview for primary care physicians.  Singapore Med J . 2019;60(12):616–620. doi:10.11622/smedj.2019158

 15.	 Castro-Apolo R, Huang JF, Vinan-Vega M, Tatum WO. Outcome and  predictive factors in post-stroke seizures: A retrospective case-con­ trol study.  Seizure . 2018;62:11–16. doi:10.1016/j.seizure.2018.09.007

 16.	 Lambertsen KL, Finsen B, Clausen BH. Post-stroke inflammation:  Target or tool for therapy?  Acta Neuro path ol . 2019;137(5):693–714.  doi:10.1007/s00401-018-1930-z

 17.	 Lambertsen KL, Biber K, Finsen B. Inflammatory cytokines in experi­ mental and human stroke.  J Cereb Blood Flow Metab . 2012;32(9):1677– 1698. doi:10.1038/jcbfm.2012.88

 18.	 Sharma R, Leung WL, Zamani A, O’Brien TJ, Casillas Espinosa PM, 
 Semple BD. Neuro inflammation in post-traumatic epilepsy: Patho­ physiology and tractable therapeutic targets.  Brain Sci . 2019;9(11):318.  doi:10.3390/brainsci9110318

 19.	 Wu XF, Li C, Yang G, et al. Scorpion venom heat-resistant peptide atten­ uates microglia activation and neuro inflammation.  Front Pharmacol . 
 2021;12:704715. doi:10.3389/fphar.2021.704715

 20.	 Viviani B, Bartesaghi S, Gardoni F, et al. Interleukin-1beta enhances 
 NMDA receptor-mediated intracellular calcium increase through acti­ vation of the Src family of kinases.  J Neurosci . 2003;23(25):8692–8700. 
 doi:10.1523/JNEUROSCI.23-25-08692.2003

 21.	 Spulber S, Bartfai T, Schultz berg M. IL-1/IL-1ra balance in the brain revis­ ited: Evidence from transgenic mouse models.  Brain Behav Immun . 
 2009;23(5):573–579. doi:10.1016/j.bbi.2009.02.015

 22.	 Iori  $\vee,$   Frigerio F, Vezzani A. Modulation of neuronal excitability by  immune mediators in epilepsy.  Curr Opin Pharmacol . 2016;26:118–123. 
 doi:10.1016/j.coph.2015.11.002

 23.	 Song B, Lee SJ, Kim CH. Roles of cytokines in the temporal chang­ es of microglial membrane currents and neuronal excitability and  synaptic efficacy in ATP-induced cortical injury model.  Int J Mol Sci .  2021;22(13):6853. doi:10.3390/ijms22136853

 24.	 Pug a zhen thi S, Zhang Y, Bouchard R, Mahaffey G. Induction of  an inflammatory loop by interleukin-  $^{1\upbeta}$   and tumor necrosis factor-α  involves NF $\tt\cdot k B$   and STAT-1 in differentiated human neuro progenitor  cells.  PLoS One . 2013;8(7):e69585. doi:10.1371/journal.pone.0069585

 25.	 del Rey A, Balschun D, Wetzel W, Randolf A, Besedovsky HO. A cytokine  network involving brain-borne IL-1β, IL-1ra, IL-18, IL-6, and TNFα oper­ ates during long-term potenti ation and learning.  Brain Behav Immun . 
 2013;33:15–23. doi:10.1016/j.bbi.2013.05.011  

26.	 Yin P, Li Z, Wang YY, et al. Neonatal immune challenge exacerbates  seizure-induced hippocampus-dependent memory impairment  in adult rats.  Epilepsy Behav . 2013;27(1):9–17. doi:10.1016/j.yebeh.
 2012.12.015

27.	 Vezzani A, Moneta D, Richichi C, et al. Functional role of inflamma­ tory cytokines and anti inflammatory molecules in seizures and epi­ le p to genesis.  Epilepsia . 2002;43(Suppl 5):30–35. doi:10.1046/j.1528- 1157.43.s.5.14.x

 28.	 Šutulović N, Grubač Ž, Šuvakov S, et al. Chronic prostatitis/chron­ ic pelvic pain syndrome increases susceptibility to seizures in rats  and alters brain levels of IL $^{1\upbeta}$   and IL-6.  Epilepsy Res . 2019;153:19–27.  doi:10.1016/j.eplepsyres.2019.03.014

 29.	 Xu D, Miller SD, Koh S. Immune mechanisms in e pile p to genesis. 
 Front Cell Neurosci . 2013;7:195. doi:10.3389/fncel.2013.00195

 30.	 Meini A, Benocci A, Frosini M, et al. Nitric oxide modulation of inter­ leukin-1[beta]-evoked intracellular   $\mathsf{C}\mathsf{a}^{2+}$   release in human astrocy­ toma U-373 MG cells and brain striatal slices.  J Neurosci . 2000;20(24):
 8980–8986. doi:10.1523/JNEUROSCI.20-24-08980.2000

31.	 Zhu G, Okada M, Yoshida S, et al. Effects of interleukin-  $^{1\upbeta}$  on hip­ pocampal glutamate and GABA releases associated with   $\mathsf{C a}^{2+}$  - induced   $\mathsf{C a^{2+}}$   releasing systems.  Epilepsy Res . 2006;71(2–3):107–116.  doi:10.1016/j.eplepsyres.2006.05.017

 32.	 Hu S, Sheng WS, Ehrlich LC, Peterson PK, Chao CC. Cytokine effects on  glutamate uptake by human astrocytes.  Neuro immuno modulation . 
 2000;7(3):153–159. doi:10.1159/000026433

 33.	 Urazova OI, Churina EG, Hasanova RR, Novitskiy VV, Poletika VS. Asso­ ciation between polymorphisms of cytokine genes and secretion  of IL-12p70, IL-18, and IL-27 by dendritic cells in patients with pulmo­ nary tuberculosis.  Tuberculosis (Edinb) . 2019;115:56–62. doi:10.1016/j. tube.2019.02.003

 34.	 Singh M, Mastana S, Singh S, Juneja PK, Kaur T, Singh P. Promoter  polymorphisms in IL-6 gene influence pro-inflammatory cytokines  for the risk of osteoarthritis.  Cytokine . 2020;127:154985. doi:10.1016/j. cyto.2020.154985

 35.	 Dinarello CA. Immunological and inflammatory functions of the inter­ leukin-1 family.  Annu Rev Immunol . 2009;27(1):519–550. doi:10.1146/ annurev.immunol.021908.132612

 36.	 Jahid M, Rehan-Ul-Haq, Chawla D, Avasthi R, Ahmed RS. Associa­ tion of polymorphic variants in  IL1B  gene with secretion of IL-  $^{1\upbeta}$   pro­ tein and inflammatory markers in North Indian rheumatoid arthritis  patients.  Gene . 2018;641:63–67. doi:10.1016/j.gene.2017.10.051

 37.	 Liu W, Yang Z, Yan T, Zhang H, Liu R. Associations of the IL-1B level,  IL-1A and IL-1B gene polymorphisms and ankylosing s pond yl it is risk  in a Chinese Han population.  Cytokine . 2020;126:154918. doi:10.1016/j. cyto.2019.154918

 38.	 Wang J, Shi Y, Wang G, Dong S, Yang D, Zuo X. The association  between interleukin-1 polymorphisms and their protein expression  in Chinese Han patients with breast cancer.  Mol Genet Genomic Med . 
 2019;7(8):e804. doi:10.1002/mgg3.804  